|
1 | 1 | <?xml version="1.0" encoding="UTF-8"?> |
2 | 2 | <clinical_study> |
3 | | - <!-- This xml conforms to an XML Schema at: |
4 | | - https://clinicaltrials.gov/ct2/html/images/info/public.xsd --> |
5 | 3 | <required_header> |
6 | | - <download_date>ClinicalTrials.gov processed this data on July 19, 2020</download_date> |
| 4 | + <download_date>11ClinicalTrials.gov processed this data on July 19, 2020</download_date> |
| 5 | + <link_text>Link to the current ClinicalTrials.gov record.</link_text> |
| 6 | + <url>https://clinicaltrials.gov/show/NCT03874338</url> |
| 7 | + </required_header> |
| 8 | + <required_header> |
| 9 | + <download_date>22ClinicalTrials.gov processed this data on July 19, 2020</download_date> |
7 | 10 | <link_text>Link to the current ClinicalTrials.gov record.</link_text> |
8 | 11 | <url>https://clinicaltrials.gov/show/NCT03874338</url> |
9 | 12 | </required_header> |
10 | | - <id_info> |
11 | | - <org_study_id>18-01323</org_study_id> |
12 | | - <secondary_id>1R01HL146206</secondary_id> |
13 | | - <nct_id>NCT03874338</nct_id> |
14 | | - </id_info> |
15 | | - <brief_title>CLEAR SYNERGY Neutrophil Substudy</brief_title> |
16 | | - <official_title>Studies on the Effects of Colchicine on Neutrophil Biology in Acute Myocardial Infarction: A Substudy of the CLEAR SYNERGY (OASIS 9) Trial</official_title> |
| 13 | + <required_header> |
| 14 | + <download_date>ClinicalTrials.gov processed this data on July 19, 2020</download_date> |
| 15 | + <link_text>Link to the current ClinicalTrials.gov record.</link_text> |
| 16 | + <url>https://clinicaltrials.gov/show/NCT03874338</url> |
| 17 | + </required_header><required_header> |
| 18 | + <download_date>ClinicalTrials.gov processed this data on July 19, 2020</download_date> |
| 19 | + <link_text>Link to the current ClinicalTrials.gov record.</link_text> |
| 20 | + <url>https://clinicaltrials.gov/show/NCT03874338</url> |
| 21 | +</required_header> |
17 | 22 | <sponsors> |
18 | 23 | <lead_sponsor> |
19 | 24 | <agency>NYU Langone Health</agency> |
|
28 | 33 | <agency_class>NIH</agency_class> |
29 | 34 | </collaborator> |
30 | 35 | </sponsors> |
31 | | - <source>NYU Langone Health</source> |
32 | | - <oversight_info> |
33 | | - <has_dmc>No</has_dmc> |
34 | | - <is_fda_regulated_drug>No</is_fda_regulated_drug> |
35 | | - <is_fda_regulated_device>No</is_fda_regulated_device> |
36 | | - </oversight_info> |
37 | | - <brief_summary> |
38 | | - <textblock> |
39 | | - CLEAR SYNERGY is an international multi center 2x2 randomized placebo controlled trial of |
40 | | - </textblock> |
41 | | - </brief_summary> |
42 | | - <overall_status>Recruiting</overall_status> |
43 | | - <start_date type="Actual">March 4, 2019</start_date> |
44 | | - <completion_date type="Anticipated">February 1, 2022</completion_date> |
45 | | - <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date> |
46 | | - <study_type>Observational</study_type> |
47 | | - <has_expanded_access>No</has_expanded_access> |
48 | | - <study_design_info> |
49 | | - <observational_model>Other</observational_model> |
50 | | - <time_perspective>Prospective</time_perspective> |
51 | | - </study_design_info> |
52 | | - <primary_outcome> |
53 | | - <measure>soluble L-selectin</measure> |
54 | | - <time_frame>between baseline and 3 months</time_frame> |
55 | | - <description>Change in soluble L-selectin between baseline and 3 mo after STEMI in the placebo vs. colchicine groups.</description> |
56 | | - </primary_outcome> |
57 | | - <secondary_outcome> |
58 | | - <measure>Other soluble markers of neutrophil activity</measure> |
59 | | - <time_frame>between baseline and 3 months</time_frame> |
60 | | - <description>Other markers of neutrophil activity will be evaluated at baseline and 3 months after STEMI (myeloperoxidase, matrix metalloproteinase-9, neutrophil gelatinase-associated lipocalin, neutrophil elastase, intercellular/vascular cellular adhesion molecules)</description> |
61 | | - </secondary_outcome> |
62 | | - <secondary_outcome> |
63 | | - <measure>Markers of systemic inflammation</measure> |
64 | | - <time_frame>between baseline and 3 months</time_frame> |
65 | | - <description>Markers of systemic inflammation will be evaluated at baseline and 3 months after STEMI (high sensitive CRP, IL-1β)</description> |
66 | | - </secondary_outcome> |
67 | | - <secondary_outcome> |
68 | | - <measure>Neutrophil-driven responses that may further propagate injury</measure> |
69 | | - <time_frame>between baseline and 3 months</time_frame> |
70 | | - <description>Neutrophil-driven responses that may further propagate injury will be evaluated at baseline and 3 months after STEMI (neutrophil extracellular traps, neutrophil-derived microparticles)</description> |
71 | | - </secondary_outcome> |
72 | | - <number_of_groups>2</number_of_groups> |
73 | | - <enrollment type="Anticipated">670</enrollment> |
74 | | - <condition>Neutrophils.Hypersegmented ; Bld-Ser-Plas</condition> |
75 | | - <condition>STEMI - ST Elevation Myocardial Infarction</condition> |
76 | | - <arm_group> |
77 | | - <arm_group_label>Colchicine</arm_group_label> |
78 | | - </arm_group> |
79 | | - <arm_group> |
80 | | - <arm_group_label>Placebo</arm_group_label> |
81 | | - </arm_group> |
82 | | - <intervention> |
83 | | - <intervention_type>Drug</intervention_type> |
84 | | - <intervention_name>Colchicine Pill</intervention_name> |
85 | | - <description>Participants in the main CLEAR SYNERGY trial are randomized to colchicine/spironolactone versus placebo in a 2x2 factorial design. The substudy is interested in the evaluation of biospecimens obtained from patients in the colchicine vs placebo group.</description> |
86 | | - <arm_group_label>Colchicine</arm_group_label> |
87 | | - <arm_group_label>Placebo</arm_group_label> |
88 | | - </intervention> |
89 | | - <eligibility> |
90 | | - <study_pop> |
91 | | - <textblock> |
92 | | - Patients who are randomized to the drug RCT portion of the CLEAR SYNERGY (OASIS 9) trial |
93 | | - </textblock> |
94 | | - </study_pop> |
95 | | - <sampling_method>Non-Probability Sample</sampling_method> |
96 | | - <criteria> |
97 | | - <textblock> |
98 | | - Inclusion Criteria: |
99 | | - </textblock> |
100 | | - </criteria> |
101 | | - <gender>All</gender> |
102 | | - <minimum_age>19 Years</minimum_age> |
103 | | - <maximum_age>110 Years</maximum_age> |
104 | | - <healthy_volunteers>No</healthy_volunteers> |
105 | | - </eligibility> |
106 | | - <overall_official> |
107 | | - <last_name>Binita Shah, MD</last_name> |
108 | | - <role>Principal Investigator</role> |
109 | | - <affiliation>NYU School of Medicine</affiliation> |
110 | | - </overall_official> |
111 | | - <overall_contact> |
112 | | - <last_name>Fatmira Curovic</last_name> |
113 | | - <phone>646-501-9648</phone> |
114 | | - |
115 | | - </overall_contact> |
116 | | - <overall_contact_backup> |
117 | | - <last_name>Binita Shah, MD</last_name> |
118 | | - </overall_contact_backup> |
119 | | - <location> |
120 | | - <facility> |
121 | | - <name>NYU School of Medicine</name> |
122 | | - <address> |
123 | | - <city>New York</city> |
124 | | - <state>New York</state> |
125 | | - <zip>10016</zip> |
126 | | - <country>United States</country> |
127 | | - </address> |
128 | | - </facility> |
129 | | - <status>Recruiting</status> |
130 | | - <contact> |
131 | | - <last_name>Fatmira Curovic</last_name> |
132 | | - <phone>646-501-9648</phone> |
133 | | - |
134 | | - </contact> |
135 | | - <contact_backup> |
136 | | - <last_name>Binita Shah, MD</last_name> |
137 | | - </contact_backup> |
138 | | - </location> |
139 | | - <location_countries> |
140 | | - <country>United States</country> |
141 | | - </location_countries> |
142 | | - <verification_date>September 2019</verification_date> |
143 | | - <study_first_submitted>March 12, 2019</study_first_submitted> |
144 | | - <study_first_submitted_qc>March 12, 2019</study_first_submitted_qc> |
145 | | - <study_first_posted type="Actual">March 14, 2019</study_first_posted> |
146 | | - <last_update_submitted>September 10, 2019</last_update_submitted> |
147 | | - <last_update_submitted_qc>September 10, 2019</last_update_submitted_qc> |
148 | | - <last_update_posted type="Actual">September 12, 2019</last_update_posted> |
149 | | - <responsible_party> |
150 | | - <responsible_party_type>Principal Investigator</responsible_party_type> |
151 | | - <investigator_affiliation>NYU Langone Health</investigator_affiliation> |
152 | | - <investigator_full_name>Binita Shah</investigator_full_name> |
153 | | - <investigator_title>Assistant Professor of Medicine</investigator_title> |
154 | | - </responsible_party> |
155 | | - <condition_browse> |
156 | | - <!-- CAUTION: The following MeSH terms are assigned with an imperfect algorithm --> |
157 | | - <mesh_term>Myocardial Infarction</mesh_term> |
158 | | - <mesh_term>ST Elevation Myocardial Infarction</mesh_term> |
159 | | - <mesh_term>Infarction</mesh_term> |
160 | | - </condition_browse> |
161 | | - <intervention_browse> |
162 | | - <!-- CAUTION: The following MeSH terms are assigned with an imperfect algorithm --> |
163 | | - <mesh_term>Colchicine</mesh_term> |
164 | | - </intervention_browse> |
165 | | - <patient_data> |
166 | | - <sharing_ipd>No</sharing_ipd> |
167 | | - </patient_data> |
168 | | - <!-- Results have not yet been posted for this study --> |
169 | 36 | </clinical_study> |
0 commit comments